Retina

Dilsher S. Dhoot, MD, and A. Paul Chous, MA, OD, FAAO, discuss the transition of care from ophthalmologist to optometrist once a patient has completed active treatment for retinal eye disease.

Experts in the field of retinal eye disorders discuss the role of injectable anti-VEGF inhibitors and how they have changed the treatment landscape.

According to review, patients with mild DR at baseline fare better

Impact of native lipids on rhodopsin signaling and regeneration opens door to GPCR drug discovery in native membrane environments

The trial marks the first-ever in vivo delivery of an experimental CRISPR gene editing medicine to a pediatric patient, with the company on track to complete dosing of the pediatric mid-dose cohort in the first half of 2022.

According to researchers at the University of California, Irvine, base editing may provide long-lasting retinal protection and prevent vision deterioration in patients with inherited retinal degeneration, specifically in Leber congenital amaurosis patients.

Dilsher S. Dhoot, MD, leads a discussion about the treatment landscape of retinal eye disorders.

Key opinion leaders discuss how co-management affects the patient-provider relationship in the treatment of retinal eye disorders.

According to the company, the modifier gene therapy candidate is for the treatment of retinitis pigmentosa resulting from mutations in the nuclear receptor subfamily 2 group E member 3 and Rhodopsin genes.

Investigators at the International Center for Materials Nanoarchitectonics have developed the first-ever artificial retinal device that increases the edge contrast between lighter and darker areas of an image, using ionic migration and interaction within solid.

The company’s announcement marks first clinical trial in humans of Ocugen’s modifier gene therapy platform.

A University of Houston study found that minorities have fewer eye exams, higher instances of disease.

If the BLA is approved, the company could receive 12 years of marketing exclusivity for an FDA-approved alternative for the most frequently used anti-VEGF treatment in wet AMD patients in the United States.

The company is planning a Phase 2 trial with an optimized formulation in wet AMD that is expected to start in fourth quarter of 2022.

A. Paul Chous, MA, OD, FAAO, leads a discussion about the optimal circumstances for optometrists and ophthalmologists to work together to manage a patient with retinal eye disorders.

Experts in the field of retinal eye disorders discuss how the COVID-19 pandemic and use of telemedicine has affected communication between optometrists, ophthalmologists, patients, and providers.

Mark Packer, MD, shares his perspective on the relationship between ICL implantation or LASIK and retinal detachment.

Lower doses vs higher ones are equally effective for treating disease

Investigators have questioned the potential for the vascular density to be a biomarker for microvascular abnormalities following COVID-19 and found that longitudinal studies are needed to determine this.

According to the company, VVN001 demonstrated clinical and statistical superiority over vehicle in reducing total and sub-regional corneal fluorescein staining scores.

A team of investigators at the Okinawa Institute of Science and Technology Graduate University in Japan have identified a gene necessary for the survival of retinal ganglion cells – a class of neurons located in the retina that are critical for vision.

The company notes that its clinical trial of the light delivery system meets the primary efficacy endpoint, and can offer hope to patients with dry AMD who are experiencing vision loss and currently have limited treatment options.

Experts in the field of retinal eye disorders talk about the role of ophthalmologists and optometrists in regard to patient education and communication.

Dilsher S. Dhoot, MD, and A. Paul Chous, MA, OD, FAAO, discuss the American Academy of Ophthalmology (AAO) guidelines on co-management between optometrists and ophthalmologists in retinal eye disorders.

Provides safe, effective injection to target choroidal, retinal tissues

Jorge Calzada, MD, shares his use of MicroPulse laser technology to combat central serous retinopathy (CSR).

According to a team of investigators at University of California, Berkeley, tests of the drug Antabuse could prove the role of hyperactive retinal cells in blindness, potentially leading to better therapies.

Investigators find that hybrid cells could be a potential therapeutic strategy to treat retinal damage and visual impairment.

"Tell Me Your Secrets" is the theme of the virtual April 2 event, which is expected to build on the foundation established during the first program held last fall.

Researchers from the Department of Ophthalmology at the University Hospital Bonn and Deutsches Zentrum für Neurodegenerative Erkrankungen suggest that assessments of the eye’s retina could help to detect a loss of brain substance, i. e. “brain atrophy.” The findings are based on data from the Rhineland Study.